Effectiveness And Safety Of Dalteparin In Patients With Acute Coronary Syndromes Without ST Elevations In Clinical Practice

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Pfizer
ClinicalTrials.gov Identifier:
NCT00922766
First received: June 16, 2009
Last updated: January 19, 2012
Last verified: January 2012
Results First Received: October 7, 2011  
Study Type: Observational
Study Design: Observational Model: Case-Only;   Time Perspective: Prospective
Condition: Acute Coronary Syndrome
Intervention: Drug: Dalteparin

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
No text entered.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
A total of 618 participants were screened, of which 617 participant were assigned to study treatment and 1 participant was excluded based on investigator's discretion.

Reporting Groups
  Description
Dalteparin Dalteparin Sodium 120 international units/kilogram (IU/kg) total body weight up to a maximum dose of 10,000 IU subcutaneously (s.c.) every 12 hours, for 1-2 weeks.

Participant Flow:   Overall Study
    Dalteparin  
STARTED     617  
COMPLETED     610  
NOT COMPLETED     7  
Death                 3  
Withdrawal by Subject                 2  
Unspecified                 1  
Adverse Event                 1  



  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
  Description
Dalteparin Dalteparin Sodium 120 international units/kilogram (IU/kg) total body weight up to a maximum dose of 10,000 IU subcutaneously (s.c.) every 12 hours, for 1-2 weeks.

Baseline Measures
    Dalteparin  
Number of Participants  
[units: participants]
  617  
Age  
[units: years]
Mean ± Standard Deviation
  57.5  ± 12.6  
Gender  
[units: participants]
 
Female     249  
Male     368  



  Outcome Measures
  Show All Outcome Measures

1.  Primary:   Number of Participants With Death or Myocardial Infarction (MI)   [ Time Frame: Baseline to 28 days after last dose of study drug ]

2.  Primary:   Number of Participants With Major Bleeding Events   [ Time Frame: Baseline to 28 days after last dose of study drug ]

3.  Primary:   Number of Participants With Minor Bleeding Events   [ Time Frame: Baseline to 28 days after last dose of study drug ]
  Hide Outcome Measure 3

Measure Type Primary
Measure Title Number of Participants With Minor Bleeding Events
Measure Description Bleeding events like hematuria, wound hematoma or injection site hematoma which did not fulfill the criteria for a major bleeding episode were classified as minor bleeding.
Time Frame Baseline to 28 days after last dose of study drug  
Safety Issue Yes  

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
FAS included all enrolled participants who received at least 1 dose of the study medication.

Reporting Groups
  Description
Dalteparin Dalteparin Sodium 120 international units/kilogram (IU/kg) total body weight up to a maximum dose of 10,000 IU subcutaneously (s.c.) every 12 hours, for 1-2 weeks.

Measured Values
    Dalteparin  
Number of Participants Analyzed  
[units: participants]
  617  
Number of Participants With Minor Bleeding Events  
[units: Participants]
  1  

No statistical analysis provided for Number of Participants With Minor Bleeding Events



4.  Other Pre-specified:   Number of Participants With Stroke   [ Time Frame: Baseline to 28 days after last dose of study drug ]

5.  Other Pre-specified:   Number of Participants With Cardiac Arrest- Resuscitated   [ Time Frame: Baseline to 28 days after last dose of study drug ]

6.  Other Pre-specified:   Number of Participants With Heparin Induced Thrombocytopenia   [ Time Frame: Baseline to 28 days after last dose of study drug ]


  Serious Adverse Events


  Other Adverse Events


  More Information
  Hide More Information

Certain Agreements:  
Principal Investigators are NOT employed by the organization sponsoring the study.
There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.
The agreement is:
unchecked The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.
unchecked The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.


Limitations and Caveats
Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.  


Results Point of Contact:  
Name/Title: Pfizer ClinicalTrials.gov Call Center
Organization: Pfizer, Inc.
phone: 1-800-718-1021
e-mail: ClinicalTrials.gov_Inquiries@pfizer.com


No publications provided


Responsible Party: Pfizer
ClinicalTrials.gov Identifier: NCT00922766     History of Changes
Other Study ID Numbers: A6301088
Study First Received: June 16, 2009
Results First Received: October 7, 2011
Last Updated: January 19, 2012
Health Authority: India: Institutional Review Board